Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy

Reproductive Toxicology

Volumn 10, Issue 6, 1996, Pages 439-446

  Manson, Jeanne M ^a   Freyssinges, Cecile ^b   Ducrocq, Marie B ^b   Stephenson, Wendy P ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

lovastatin; pregnancy; simvastatin

Indexed keywords

DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; SIMVASTATIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL SYNTHESIS; COMPARATIVE STUDY; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG MARKETING; FEMALE; FETUS DEATH; GASTROSCHISIS; HIGH RISK PREGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; RAT; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICHOLESTEREMIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; PREGNANCY; PREGNANCY COMPLICATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; SIMVASTATIN;

EID: 0030293837     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(96)00130-X     Document Type: Article

References (23)

1. 1. Tobert JA, Bell GD, Birtwell J, et al. Cholesterol lowering effect of mevinolin, an inhibitor of 3 hydroxy-3-methylglutaryl-coenzyme A reductase in healthy volunteers. J Clin Invest. 1982; 69:1913-9.
2. 2. Grundy SM. HMG-CoA reductase inhibitor for treatment of hypercholesterolemia. N Engl Med. 1988;319:24-33.
3. 3. Alberts AW, Chen J, Kuron G et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 1980;77:3957-61.
4. 4. McKenney JM. Lovastatin: a new cholesterol-lowering agent. Clin Pharmacol. 1988;7:21-36.
5. 5. Bresow J. Hypercholesterolemia. In Buyse ML, ed. Birth defects encyclopedia. Cambridge. MA: Blackwell Scientific Publications; 1990:898-9.
6. 6. Gotto AM, Bierman EL, Connor WE, et al. Recommendations for treatment of hyperlipidemia in adults: a joint statement of the nutrition committee and the council on arteriosclerosis. Circulation. 1984;69:1067A-90A.
7. 7. Weinberg RB. Lipoprotein metabolism: hormonal regulation. Hosp Pract. 1987;June 15:125-45.
8. 8. Salameh WA, Mastrogiannis DS. Maternal hyperlipidemia in pregnancy. Clin Obstet Gynecol. 1994;37:66-77.
9. 9. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Teratology. 1983;28:449-56.
10. 10. Wise LD, Minsker DH, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin MK-0733 oral fertility study in rats. Pharmacometrics. 1990;39:127-42.
11. 11. Wise LD, Majka JA, Robertson RT, Bokelman DL, Nakatsuka T, Akutsu S, Fujii T. Simvastatin MK-0733 oral teratogenicity study in rats prenatal and postnatal observations. Pharmacometrics. 1990;39:143-58.
12. 12. Wise LD, Prahalada S, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin MK-0733 oral teratogenicity study in rabbits. Pharmacometrics. 1990;39:159-68.
13. 13. Physician's Desk Reference (PDR). Mevacor® (Lovastatin), 49th ed. Montvale, NJ: Medical Economics; 1995:1584-8.
14. 14. Physician's Desk Reference (PDR). Zocor® (Simvastatin). 49th ed. Montvale, NJ: Medical Economics; 1995:1655-8.
15. 15. Centers for Disease Control and Prevention (CDC). Morbidity and mortality weekly report 1993;42,22 October.
16. 16. Mitchell A. Special considerations in studies of drug-induced birth defects. In Strom BL, ed. Pharmacoepidemiology (2nd ed). New York: John Wiley and Sons; 1994:595-608.
17. 17. Moore KL, Persaud TVN, Shiota K. Color atlas of human embryology. Philadelphia, PA: W.B. Saunders; 1993:107.
18. 18. Larsen WJ. Human embryology. New York: Churchill Livingstone; 1993.
19. 19. Ghindini A, Sicherer S, Willner J. Congenital abnormalities (VATER) in baby born to mother using lovastatin (letter). Lancet. 1992;339:1416-7.
20. 20. Quan L, Smith DW. The VATER association: vertebral defects, anal atresia, T-E fistula with esophageal atresia, radial and renal dysplasia: a spectrum of associated detects. J. Pediatr. 1973;82: 104-7.
21. 21. Toriella HV. Holoprosencephaly. In Buyse ML, ed. Birth defects encyclopedia. Cambridge, MA:Blackwell Scientific Publications; 1990:876-7.
22. 22. Rosa F. Anticholesterol agent pregnancy exposure outcomes. Reprod Toxicol. 1994;8:446.
23. 23. Schardein JL. Chemically induced birth defects. New York: Marcel Dekker; 1993:14.